Amgen Invests $300M in Puerto Rico Manufacturing Expansion

What happened

Amgen announced a $300 million investment in its Puerto Rico operations to further expand its U.S. manufacturing footprint, aligning with its previously disclosed ~$2.6 billion capex plan for 2026. The investment supports production capacity for its growing pipeline, including the obesity drug MariTide, and adds to new biologics plants in Ohio and North Carolina. However, this capital intensity comes at a time when the company faces elevated leverage (~3.2x–4.1x net debt/EBITDA) and policy-driven erosion on legacy drugs like ENBREL and Prolia. While the investment strengthens long-term supply chain resilience, it does not address near-term revenue headwinds from IRA price cuts and biosimilar competition. The announcement is consistent with management's strategy but does not alter the fundamental risk-reward profile.

Implication

For investors, this announcement confirms management's commitment to expanding manufacturing capacity, especially ahead of potential MariTide commercial scale-up, but it also underscores the rising capex burden that will consume free cash flow over the next 12–18 months. The master report already flagged 2026 capex of ~$2.6B as a near-term cash flow drag, and this $300M addition is consistent with that trajectory. Amgen's ability to deleverage while funding these investments will be a key test, especially if legacy revenue erosion accelerates. The Puerto Rico expansion also supports geographic diversification of supply, which could mitigate some regulatory risk, but does not offset the central thesis that valuation (23.7x P/E) already prices in significant growth optionality. We see no reason to adjust our POTENTIAL SELL rating or $370 trim/$295 attractive entry levels based on this news alone.

Thesis delta

The $300M Puerto Rico investment is a routine capital allocation decision that fits squarely within Amgen's previously disclosed manufacturing expansion plan. It does not alter the fundamental outlook: the company still faces erosion from IRA/biosimilar pressure, elevated leverage, and a binary MariTide outcome. The thesis remains that current valuations offer a poor risk-reward until these uncertainties are resolved, and this news does not change that assessment.